Why Codex DNA Trounced the Market Today

Wednesday will go down in history for Codex DNA (NASDAQ: DNAY). The genetics-focused biotech saw its share price rocket 39% higher, thanks to a potentially very lucrative deal with a deep-pocketed pharmaceutical giant.

Codex DNA disclosed in a regulatory filing that it has entered into a research collaboration and license agreement with U.S. pharmaceutical company Pfizer (NYSE: PFE), these days best known as the co-developer of the Comirnaty coronavirus vaccine.

Image source: Getty Images.

Continue reading

Source Fool.com